Skip to Main Content

Riding the coattails of CAR-T cancer therapies, scientists have begun to explore a spin-off: using similar immune cells to treat autoimmune diseases such as type 1 diabetes and prevent rejection of transplanted organs.

In CAR-T therapies, T cells are extracted from a patient’s blood, reprogrammed to attack cancer cells, and then re-infused into the bloodstream to carry out their new assignment.


Scientists – including those at Caladrius Biosciences and TxCell – are now engineering a subgroup of these immune cells, called T regulatory cells, or Tregs, in hopes of tamping down the wayward parts of the immune system responsible for autoimmune diseases and organ rejection.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!